DeutschNewstral
Article
bizjournals.com on 2016-01-15 15:36
Shares of Cambridge biotech Sarepta crash after harsh FDA review
Related news
- FSarepta shares surge 90% on FDA approvalft.com
- MSarepta Therapeutics shares dive on safety issues in FDA databasemarketwatch.com
Sarepta Shares Plunge as FDA Raises Doubts About Drugwsj.com- Cambridge biotech Sarepta tops $11B market cap on gene therapy databizjournals.com
- MSarepta Therapeutics shares jump on news of critic’s departure from FDAmarketwatch.com
Shares of Boston biotech dice as FDA halts clinical trialBoston Herald- MPuma Biotech shares jump on breast cancer study, FDA applicationmarketwatch.com
- Sarepta sells FDA review voucher for $125M, but analyst questions pricebizjournals.com
- Latest data from Cambridge’s Sarepta bodes well for FDA approval of Duchenne drugbizjournals.com
- BSarepta Could Triple on Expedited FDA Approvalbarrons.com
- FDA approves Cambridge biotech's pancreatic cancer drugbizjournals.com
Sarepta Tumbles With Latest Comments from FDAForbes- Top two executives at embattled Cambridge biotech Aegerion resignbizjournals.com
- Merck takes stake in small Cambridge rare disease biotech, lifting sharesbizjournals.com
- Shares of Cambridge biotech plunge as postpartum drug fails late-stage trialbizjournals.com
- MKrystal Biotech shares up 27% after company's skin drug receives expedited review designation from FDAmarketwatch.com
Shares in Vancouver biotech firm plunge after FDA finds ‘no clinical benefit’ to COVID-19 drugoregonlive.com- FDA approves Cambridge biotech's first-ever drug for cancerbizjournals.com
- BSarepta Slammed by FDA, Stock Is Now Intriguingbarrons.com